Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
| Price | $5.10 |
|---|---|
| Market cap | $415,329 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 4.648-25.9 |
| Beta | 0.17 |
Explore NIKI's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.